[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
Last updated December 3, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

623.P1.79 Lymphoma: Chemotherapy, excluding Pre-Clinical Models Poster I

Oral and Poster Abstracts
Poster Session
Saturday, December 5, 2009: 5:30 PM-7:30 PM
Hall E (Ernest N. Morial Convention Center)
Final Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL)

Richard Piekarz, MD, PhD1*, John Wright, MD, PhD2*, Robin Frye, RN1*, Steven L Allen, MD3, David Joske, MBBS, FRCPA, FRACP4, Mark Kirschbaum, MD5, Ian D. Lewis, MD6, Miles Prince, MD, MRACMA, FRACP, FRCPA7*, Sonali Smith, MD8, Elaine S Jaffe, MD9 and Susan Bates, MD1*

1National Cancer Institute, Bethesda, MD
2IDB CTEP NCI, Rockville, MD
3North Shore University Hospital, Lake Success, NY
4Haematology Care Center, Sir Charles Gairdner Hospital, Perth, WEA, Australia
5Division of Hematology, City of Hope National Medical Center, Duarte, CA
6Division of Haematology, I.M.V.S., Adelaide, SA, Australia
7Peter MacCallum Cencer Centre, East Melbourne, Australia
8University of Chicago, Chicago, IL
9Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

Preliminary Results of a Phase II Trial with the Multikinase Inhibitor Sorafenib in Heavily Pretreated Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)

Anna Guidetti, MD1*, Carmelo Carlo-Stella, MD2, Liliana Devizzi, MD1*, Paola Matteucci, MD1*, Alfonso Marchianò, MD3*, Rodolfo Lanocita, MD3*, Michele Magni, MD1*, Anna Dodero, MD4*, Corrado Tarella, MD5*, Massimo Di Nicola, MD1*, Paolo Corradini, MD6 and Alessandro M. Gianni, MD2*

1Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
2Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori and University of Milano, Milano, Italy
3Radiology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
4Ematologia-Trapianto di Midollo Osseo, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
5Ematologia e Terapie Cellulari, Mauriziano Hospital and University of Torino, Torino, Italy
6Fondazione IRCCS Istituto Nazionale Tumori and University of Milano, Milano, Italy

Predictive role of Early Interim FDG-PET in Hodgkin Lymphoma

Vittorio Stefoni1*, Alessandro Broccoli2*, Lapo Alinari3, Valentina Ambrosini4*, Enrico Derenzini2*, Stefano Fanti4*, Mariapaola Fina2*, Letizia Gandolfi2*, Enrica Marchi5*, Cinzia Pellegrini2*, Federica Quirini2*, Pier Luigi Zinzani2 and Michele Baccarani2*

1On the behalf of Intergruppo Italiano Linfomi (IIL), Hematology 2, AOU San Giovanni Battista, Torino, Italy
2Institute of Hematology and Medical Oncology “L. & A. Seràgnoli”, Bologna, Italy
3Comprehensive Cancer Center, Ohio State University, Columbus, OH
4Department of Nuclear Medicine, University of Bologna, Bologna, Italy
5Irving Herbert Cancer Center, New York, NY

Aggressive Primary Chemotherapy Plus Autologous Stem Cell Transplantation Improves Outcome for Peripheral T Cell Lymphomas Compared with CHOP-Like Regimens

Michal Sieniawski1, James Lennard1*, Christopher Millar2*, Simon Lyons3*, Philip Mounter4*, Zor Maung4*, Stephen J. Proctor1* and Anne L. Lennard1*

1Haematological Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom
2Department of Haematology, The James Cook University Hospital, Middlesbrough, United Kingdom
3Department of Haematology, Sunderland Royal Hospital, Sunderland, United Kingdom
4Department of Haematology, University Hospital of North Tees, Stockton on Tees, United Kingdom

The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405 – A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL

Brad S Kahl, MD1, Hailun Li, Ph.D.2*, Mitchell R Smith, MD, PhD3, Randy D. Gascoyne, MD4, Elisabeth Paietta, MD5, Ranjana Advani, MD6 and Sandra J Horning, MD6

1Department of Medicine, Section of Hematology/Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI
2Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA
3Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA
4Pathology, British Columbia Cancer Agency, Vancouver, Canada
5Cancer Center, Montefiore Medical Center North Division, Bronx, NY
6Stanford University, Stanford, CA

Safety and Efficacy of Bendamustine with or without Rituximab for the Treatment of Heavily Pretreated CLL and Lymphoma Patients. A Multicenter Retrospective Study

Luigi Rigacci1*, Benedetta Puccini1*, Enrico Orciuolo2*, Alfonso D'Arco3*, Sergio Storti4*, Gianluca Gaidano5*, Roberto Freilone6*, Nicola Di Renzo, MD7*, Caterina Patti, MD8*, Alessandro Isidori, MD, PhD9, Pier Luigi Zinzani, MD10*, Marco Gobbi, MD11*, Pellegrino Musto, MD12, Anna Marina Liberati, MD13*, Andrea Carpaneto14*, Sergio Cortelazzo15, Nicola Cascavilla, MD16*, Nadia Cecconi2*, Valeria Belsito Petrizzi3*, Giulio Giordano, MD4*, Silvia Franceschetti5*, Atto Billio7* and Alberto Bosi, MD1*

1Hematology, Careggi Hospital, Firenze, Italy
2Dept. of Oncology, Transplants and Advanced Technologies, Hematology, University of Pisa, Pisa, Italy
3UO Onco-Ematologia Nocera Inferiore, Nocera Inferiore, Italy
4UOC di Onco-Ematologia Campobasso, Campobasso, Italy
5Division of Hematology, Department of Clinical and Experimental Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
6On the behalf of Intergruppo Italiano Linfomi (IIL), Hematology 2, AOU San Giovanni Battista, Torino, Italy
7Unità di Ematologia, Ospedale Vito Fazzi, Lecce, Italy, Lecce, Italy
8Dept. of Hematology, Ospedale V. Cervello, Palermo, Italy
9Hematology and Stem Cell Transplant Cent, San Salvatore Hospital, Pesaro (PU), Italy
10Institute of Hematology L. e A. Seragnoli, Department of Hematology/Oncology, University of Bologna, Bologna, Italy
11Dipartimento di Ematologia e Oncologia, Università di Genova, Italy, Genova, Italy
12CROB Rionero in Vulture, Roma, Italy
13Haematology, AO S.Maria Policlinico Monteluce, Terni, Italy
14Hematology, “Sant'Anna” di Ronciglione, Viterbo, Italy
15Department of Haematology and Bone Marrow Transplantation, Regional Hospital, S. Maurizio, Bolzano/Bozen, Italy
16Ematologia e TMO, Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG), Italy

Efficacy and Safety of Liposomal Cytarabine as Intrathecal Prophylaxis in Patients with Diffuse Large B Cell Lymphoma at High Risk of CNS Involvement: A Multicentric Study Including 80 Patients in Spain

Adolfo de la Fuente Sr.1*, Antonio Salar, MD, PhD2*, Carlos Panizo, MD3*, Belen Navarro Sr.4*, Teresa Olave5*, María Jesus Peñarrubia, MD6*, Joaquín Herrero, MD, PhD7*, Jose Francisco Tomas1, Miguel Canales8 and Eva González-Barca9*

1Hematology-BMT Unit, MD Anderson Spain, Madrid, Spain
2Hematology Department, Hospital del Mar, Barcelona, Spain
3Hematology & Cell Therapy Prog., Clinica Universitaria de Navarra, Pamplona, Spain
4Puerta de HIerro, Madrid, Spain
5Clinico Lozano Blesa, Zaragoza, Spain
6HOSPITAL RÍO HORTEGA, Valladolid, Spain
7Oncología, Avd. Pintor Baeza s/n, Alicante, Alicante, Spain
8Hospital Universitario La Paz, Madrid
9Institut Catalá d'Oncología-Hospital Duran i Reynals, Barcelona

Biweekly Rituximab, Cyclophosphamide, Vincristine, Non-Pegylated Liposome-Encapsulated Doxorubicin (Myocet®) and Prednisone (R-COMP-14) as Induction Treatment in Poor R-IPI Risk Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL) and Pre-Existing Heart Disease

Ferdinando Frigeri, MD1*, Gaetano Corazzelli, MD1*, Manuela Arcamone, MD1*, Gaetana Capobianco, MD1*, Anna Lucania, MD2*, Cristina Becchimanzi, MD1*, Gianpaolo Marcacci, MD1*, Filippo Russo, MD1*, Maria Rosaria Villa, MD2*, Lucia Mastrullo, MD2* and Antonio Pinto, MD1*

1Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione ‘G. Pascale', IRCCS, Naples, Italy
2Hematology, A.O. San Gennaro, ASLNA1, Naples, Italy

A Phase II Study of Temsirolimus (CCI-779) in Combination with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Stephen M Ansell1, Hui Tang, BS, MA, PhD2*, Paul Kurtin2*, Patricia Koenig2*, David J Inwards1*, Keith Shah3* and Thomas E Witzig, MD1*

1College of Medicine, Mayo Clinic, Rochester, MN
2Mayo Clinic, Rochester, MN
3Dayton Oncology Hematology Consultants, Dayton, OH

A Novel Bayesian Prognostic Index for Diffuse Large B-Cell Lymphoma: A New Powerful Tool for Prediction of Outcome

Michal Sieniawski, MD1, Malcolm Farrow2*, Xiao Zhao2*, Jennifer Wilkinson1*, Tryfonia Mainou–Fowler1*, Jo White1*, John MacIntyre3* and Stephen J. Proctor1*

1Scotland and Newcastle Lymphoma Group, Newcastle University, Newcastle upon Tyne, United Kingdom
2School of Mathematics and Statistics, Newcastle University, Newcsastle upon Tyne, United Kingdom
3School of Computing and Technology, Sunderland University, Sunderland, United Kingdom

Rituximab Added to CODOX-M/IVAC has No Clear Benefit Compared to CODOX-M/IVAC alone in Adult Patients with Burkitt Lymphoma

Jeffrey A. Barnes, MD, PhD1*, Ann S. LaCasce, MD2, Yang Feng2*, Christiana Toomey1*, Donna Neuberg, ScD2*, Ephraim P. Hochberg, MD1 and Jeremy S. Abramson, MD1

1Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA
2Dana Farber Cancer Institute, Boston, MA

Prognostic Factors for Survival After 2-CdA-Based Therapy for Symptomatic Waldenström Macroglobulinemia (WM) Stratify Patients Into Low- and High-Risk Groups

Sheeba K Thomas, M.D.1, Lei Feng, M.S.2*, Kay B Delasalle, B.S.1*, Michael Wang, M.D.1*, Jatin J Shah, M.D.1, Robert Z Orlowski, M.D., Ph.D.1, Raymond Alexanian, M.D.1 and Donna M Weber, M.D.1

1Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, TX
2Department of Biostatistics, University of Texas M.D. Anderson Cancer Center, Houston, TX

A Phase I/II Trial of Lenalidomide and RCHOP (R2CHOP) in Patients with Newly Diagnosed Diffuse Large B -Cell (DLBCL) and Follicular Grade 3 Lymphoma

Grzegorz S. Nowakowski1, Betsy LaPlant2*, Thomas Habermann3*, David J Inwards4*, Patrick L Johnston, MD, PhD4*, Clive S. Zent, MD1, Craig B. Reeder, MD5 and Thomas E Witzig, MD4*

1Mayo Clinic, Rochester, MN
2Hematology, Mayo Clinic, Rochester, MN
3Mayo Foundation, Rochester, MN
4College of Medicine, Mayo Clinic, Rochester, MN
5Hematology/Oncology, Mayo Clinic, Scottsdale, AZ

Efficacy of Abbreviated Stanford V Chemotherapy and Involved Field Radiotherapy in Early Stage Hodgkin’s Disease: Mature Results of the G4 Trial

Ranjana H Advani, MD1, Richard T Hoppe, MD2*, David M. Baer, MD3, Joseph Mason, M.D4*, Saul A Rosenberg, M.D1* and Sandra J Horning, MD1

1Stanford University, Stanford, CA
2Stanford University Medical Center, Stanford, CA
3Kaiser Permanente, Oakland, CA
4Kaiser Permanente, San Jose, CA

Cardiac Toxicity Associated with the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin) in Combination with CHOP (A-CHOP) Chemotherapy for Peripheral T Cell Lymphoma (PTCL): The ECOG 2404 Trial

Ranjana H Advani, MD1, Fangxin Hong, Ph.D.2*, Kristen N. Ganjoo, MD3*, Judith B. Manola, MS4*, Lode J. Swinnen, MBChB5, Thomas M Habermann, MD6 and Sandra J Horning, MD1

1Stanford University, Stanford, CA
2Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA
3Palo Alto VAHCS, Stanford University, Palo Alto, CA
4Biostats, Dana-Farber Cancer Institute, Boston, MA
5Div. of Hem. Malignancy, Johns Hopkins Cancer Center, Baltimore, MD
6College of Medicine, Mayo Clinic, Rochester, MN

High-Dose Methotrexate, Rituximab, and Temozolomide (MRT) for Patients with Primary CNS Lymphoma (PCNSL)

Elizabeth R. Gerstner1*, Fred H Hochberg, MD2*, Scott R. Plotkin3*, April F. Eichler3* and Tracy T. Batchelor, MD4

1Neuro-Oncology, Massachusetts General Hospital Cancer Center, Boston, MA
2Department of Neurology, Massachusetts General Hospital, Boston, MA
3Massachusetts General Hospital Cancer Center, Boston, MA
4Massachusetts General Hospital, Boston, MA

A Phase I/II Trial of the Kinesin Spindle Protein (KSP) Inhibitor SB-743921 Dosed Q14D without and with Prophylactic G-CSF in Non-Hodgkin (NHL) or Hodgkin Lymphoma (HL)

Owen A O'Connor1*, J. Gerecitano2, H. Van Deventer3*, B. Afanasyev4*, J. Hainsworth5, M. Chen6*, K. Saikali6*, J. Seroogy6*, R. Escandon6*, A. Wolff6* and MG. Conlan6

1Columbia Univ., New York, NY
2Memorial Sloan-Kettering Cancer Ctr., New York, NY
3Univ. North Carolina, Chapel Hill, NC
4St. Petersburg State Med. Univ., St. Petersburg, Russia
5Sarah Cannon Cancer Ctr., Nashville, TN
6Cytokinetics, Inc., S. San Francisco, CA

Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies: Phase 1 Results

Steven M. Horwitz, MD1, Julie M. Vose, M.D.2, Ranjana Advani, MD3, Kamalesh Sankhala, MD4*, Swaminathan Padmanabhan, MD5, Paul A. Hamlin Jr., MD1, Andy Chen, MD, PhD6, Jasmine M Zain, MD7, Steven Fruchtman, MD8 and Owen A O'Connor, MD, PhD7*

1Memorial Sloan-Kettering Cancer Center, New York, NY
2University of Nebraska Medical Center, Omaha, NE
3Stanford University, Stanford, CA
4University of Texas Health Science Center at San Antonio, San Antonio, TX
5The Institute for Drug Development, CTRC at the University of Texas Health Science Center San Antonio, San Antonio, TX
6Stanford Cancer Center, Palo Alto, CA
7New York University Cancer Institute, NYU Langone Medical Center, New York, NY
8Allos Therapeutics, Inc, Westminster, CO

Safety and Management of Pralatrexate Treatment in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

Lauren Pinter-Brown1*, Steven M. Horwitz, MD2, Barbara Pro, MD3*, Pier Luigi Zinzani, MD4*, Christian Gisselbrecht, MD5, Barbara MacGregor Cortelli, RN6*, Steven Fruchtman, MD7 and Owen A O'Connor, MD, PhD6*

1University of California at Los Angeles, Los Angeles, CA
2Memorial Sloan-Kettering Cancer Center, New York, NY
3University of Texas M.D. Anderson Cancer Center, Houston, TX
4University of Bologna, Bologna, Italy
5Hopital Saint-Louis, Paris, France
6New York University Cancer Institute, NYU Langone Medical Center, New York, NY
7Allos Therapeutics, Inc, Westminster, CO

Durable Responses After Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory (R/R) Aggressive Non-Hodgkin’s Lymphoma (a-NHL): Results From An International Phase 2 Study (CC-5013-NHL-003)

Thomas E Witzig, MD1*, Julie M. Vose, M.D.2, Pier Luigi Zinzani, MD3*, Craig B. Reeder, MD4, Rena Buckstein, MD, FRCPC5, Jonathan Polikoff, MD6*, Pingshan Guo7*, Dennis Pietronigro7*, Annette Ervin-Haynes7 and Myron S Czuczman8

1College of Medicine, Mayo Clinic, Rochester, MN
2Internal Medicine Section of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE
3Institute of Hematology L. e A. Seragnoli, Department of Hematology/Oncology, University of Bologna, Bologna, Italy
4Hematology/Oncology, Mayo Clinic, Scottsdale, AZ
5Dept. of Hematology/Oncology, Sunnybrook Odette Cancer Center, Toronto, ON, Canada
6Kaiser Permanente Medical Group, San Diego, CA
7Celgene Corporation, Summit, NJ
8Medical Oncology and Immunology, Roswell Park Cancer Institute, Buffalo, NY

Phase III Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin’s Lymphoma (EXTEND):  Results From the Treatment and Follow-up Periods

Ruth Pettengell, MD1*, Bertrand Coiffier, MD2, Geetha Narayanan, MD3*, Fernando Hurtado de Mendoza, MD4*, Raghunadharao Digumarti, MD5*, Henry Gomez, MD6*, Pier Luigi Zinzani, MD7*, Gary J Schiller, MD8*, David A Rizzieri, MD9, Paul Cernohous10*, Lixia Wang10* and Jack W. Singer, MD10

1Haematology, St Georges Hospital, London, United Kingdom
2Centre Hospitalier Lyon-Sud, Pierre-Benite, France
3Dept. of Medical Oncology, Regional Cancer Centre, Trivandrum, India
4Hospital Ddgardo Rebagliati Martins, Lima, Peru
5Medical Oncology, Nizam's Institute of Medical Sciences, Hyderabad, India
6Hospital Edgardo Rebagliati Martins, Lima, Peru
7Institute of Hematology L. e A. Seragnoli, Department of Hematology/Oncology, University of Bologna, Bologna, Italy
8UCLA School of Medicine, Los Angeles, CA
9Duke University Medical Center, Durham, NC
10Cell Therapeutics, Seattle, WA

Pralatrexate Induces Responses in Patients with Highly Refractory Peripheral T-Cell Lymphoma (PTCL)

Kerry J. Savage, MD1, Andrei R. Shustov, MD2, Andre Goy, MD3, Steven M. Horwitz, MD4, Barbara Pro, MD5*, Molly Patterson, BA6*, Steven Fruchtman, MD7 and Owen A O'Connor, MD, PhD6*

1BC Cancer Agency, Vancouver, BC, Canada
2Fred Hutchinson Cancer Research Center, Seattle, WA
3Hackensack University Medical Center, Hackensack, NJ
4Memorial Sloan-Kettering Cancer Center, New York, NY
5University of Texas M.D. Anderson Cancer Center, Houston, TX
6New York University Cancer Institute, NYU Langone Medical Center, New York, NY
7Allos Therapeutics, Inc, Westminster, CO

R2: Preliminary Results of a Phase II Study of Lenalidomide and Rituximab in Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (NHL)

Mrinal Dutia, MD1, Ian DeRoock, MD2, Karen Chee, MD3*, Robert O'donnell, MD2*, Christine Quirch2*, Christine Reed-Pease2* and Joseph Tuscano, MD2

1UC Davis Cancer Center, Sacramento, CA
2Hematology - Oncology, UC Davis Medical Center, Sacramento, CA
3California Cancer Care, San Mateo, CA

Final Report of a Phase-II Study of Rituximab Plus ABVD for Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.: Results of Long Follow up and Comparison to Institutional Historical Data

Amanda R Copeland, MS1*, Yumei Cao, MD2*, Michelle Fanale, M.D.3, Luis Fayad, MD4, Peter McLaughlin5*, Barbara Pro, MD6*, Fredrick Hagemeister5*, Jorge Romaguera, MD7*, Felipe Samaniego, MD6*, Alma Rodriguez, MD8* and Anas Younes, MD9

1Department of Lymphoma and Myeloma, M.D. Anderson Cancer Center, Houston, TX
2Department of Neuroscience, Albert Einstein College of Medicine, Bronx, NY
3Lymphoma/Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, TX
4Lymphoma/Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX
5Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, TX
6Department of Lymphoma/Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, TX
7Lymphoma/Myeloma, UTMD Anderson Cancer Center, Houston
8Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
9Department of Lymphoma/Myeloma, University of Texas-M.D. Anderson Cancer Center, Houston, TX

Correlation Between Baseline Methylmalonic Acid Status and Mucositis Severity in the PROPEL Study: Implications for Vitamin Prophylaxis

Barbara Pro, MD1*, Bertrand Coiffier, MD2, Steven M. Horwitz, MD3, Adam Boyd, PhD4*, Ellen Neylon, RN5*, Steven Fruchtman, MD4 and Owen A O'Connor, MD, PhD5*

1University of Texas M.D. Anderson Cancer Center, Houston, TX
2Centre Hospitalier Lyon-Sud, Pierre-Benite, France
3Memorial Sloan-Kettering Cancer Center, New York, NY
4Allos Therapeutics, Inc, Westminster, CO
5New York University Cancer Institute, NYU Langone Medical Center, New York, NY

Phase I Study of Bortezomib in Combination with Gemcitabine in Relapsed/Refractory Intermediate Grade B-Cell and Mantle Cell Non-Hodgkin's Lymphoma

Mark Kirschbaum, MD1, Maria Delioukina2, Leslie Popplewell, MD3, David S. Snyder, MD4, Pablo Parker2*, Robert Chen, MD5, Jasmine Zain, MD6, Deron Matsuoka3*, Nony Obadike3*, Paul Frankel3*, Auayporn P. Nademanee, MD3 and Stephen J Forman, MD7

1Division of Hematology, City of Hope National Medical Center, Duarte, CA
2City of Hope, Duarte, CA
3City of Hope National Medical Center, Duarte, CA
4Division of Hematology/HCT, City of Hope National Medical Center, Duarte, CA
5hematology/HCT, City of Hope National Medical Center, Duarte, CA
6NYU Langone Medical Center, New York University Cancer Center, New York, NY
7Hem/HCT, City of Hope National Medical Center, Duarte, CA

Post-Renal Transplant De Novo Non-Skin Malignancies in Mycophenolate Mofetil- and Calcineurin Inhibitor-Based Immunosuppression

Lohith Bachegowda, MD, MRCP1*, Diptesh Gupta, MD, MRCP2*, Ajoy Bharadwaj, MD3*, Karthik Ranganna3*, TIM Adamowicz, DO1* and Anil Kumar, MD4*

1Interna Medicine, DREXEL UNIVERSITY COLLEGE OF MEDICINE, Philadelphia, PA
2Internal Medicine, UNIVERSITY MISSOURI COLUMBIA, Columbia Missouri
3Division of Nephrology, DREXEL UNIVERSITY COLLEGE OF MEDICINE, Philadelphia, PA
4TRANSPLANT Surgery, DUCOM, Philadelphia, PA

*signifies non-member of ASH